Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 7,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NERVES Clear all
Completed Phase 1Phase 2 Interventional Results available

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NCT02960230
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
K27M peptide, Nivolumab
Biological · Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 28, 2026, 6:29 AM EDT
Completed Phase 2 Interventional

High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes

NCT00463892
View directory record Official record
Conditions
Melanoma
Interventions
High-resolution contrast-enhanced MRI scan
Procedure
Lead sponsor
Redwood Regional Medical Group
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 28, 2026, 6:29 AM EDT
Recruiting Phase 2 Interventional

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

NCT05684692
View directory record Official record
Conditions
Schwannomatosis, Schwannomas, Pain, Chronic
Interventions
Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 6:29 AM EDT
Not listed Phase 2 Interventional

Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors

NCT00178698
View directory record Official record
Conditions
Neuroendocrine Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Gastric Cancer
Interventions
thermochemotherapy, Cisplatin, Gemcitabine, Interferon-a
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Oct 28, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

NCT02586987
View directory record Official record
Conditions
Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions
Selumetinib, MEDI4736, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 28, 2026, 6:29 AM EDT
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

NCT00003471
View directory record Official record
Conditions
Low-Grade Astrocytoma, Nos
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 28, 2026, 6:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Preoperative Ultrasound Guided Pectoralis Nerve Block Placement Versus Intra-operative Placement: A Prospective Randomized Trial

NCT03201809
View directory record Official record
Conditions
Post-operative Pain
Interventions
On-Q, Ultrasound guided pectoral nerve block
Device · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 28, 2026, 6:29 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

NCT05060432
View directory record Official record
Conditions
Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
Interventions
EOS-448, pembrolizumab, inupadenant, Dostarlimab, SOC chemotherapies
Drug
Lead sponsor
iTeos Belgium SA
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Diego, California • Bergen, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 28, 2026, 6:29 AM EDT
Recruiting Not applicable Interventional

Clinical Trial of Approaches to Prostate Cancer Surgery

NCT05155501
View directory record Official record
Conditions
Prostate Cancer
Interventions
Robot-assisted radical prostatectomy (RP), Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Duarte, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 28, 2026, 6:29 AM EDT
Completed No phase listed Observational

Measures of Motor Impairment in Early Parkinson's Disease

NCT00291265
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 6:29 AM EDT
Terminated Phase 2 Interventional Results available

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

NCT05753007
View directory record Official record
Conditions
Glioblastoma
Interventions
Cannabidiol (CBD), Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 28, 2026, 6:29 AM EDT
Recruiting Phase 1 Interventional

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT04897321
View directory record Official record
Conditions
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma
Interventions
Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 28, 2026, 6:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

NCT02965716
View directory record Official record
Conditions
Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Pembrolizumab, Talimogene Laherparepvec
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Mobile, Alabama • Goodyear, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 28, 2026, 6:29 AM EDT
Terminated Phase 3 Interventional

Surgery for Vocal Cord Paralysis

NCT00064571
View directory record Official record
Conditions
Unilateral Vocal Cord Paralysis
Interventions
vocal fold medialization, vocal fold reinnervation
Procedure
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
12
States / cities
Birmingham, Alabama • Irvine, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2006 · Synced Oct 28, 2026, 6:29 AM EDT
Completed Not applicable Interventional

Optimal Location of Local Anesthetic Injection for Ultrasound Guided Interscalene Block

NCT01877330
View directory record Official record
Conditions
Shoulder Arthroscopy, Ultrasound-guided Interscalene Nerve Block
Interventions
Interscalene block for shoulder arthroscopy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 28, 2026, 6:29 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Ketamine and Propofol NeuroImaging

NCT07294092
View directory record Official record
Conditions
Anesthesia, Pain
Interventions
Propofol, Ketamine, Peripheral Nerve Stimulation
Drug · Device
Lead sponsor
Keith M Vogt
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 28, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

NCT00093821
View directory record Official record
Conditions
Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
tanespimycin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 28, 2026, 6:29 AM EDT
Terminated Phase 2 Interventional

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

NCT00722098
View directory record Official record
Conditions
Malignant Melanoma Stage IV
Interventions
DC Vaccine & Cyclophosphamide, DC Vaccine & Placebo
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 28, 2026, 6:29 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 28, 2026, 6:29 AM EDT
Completed Phase 1Phase 2 Interventional

Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas

NCT01024907
View directory record Official record
Conditions
Adult Brain Tumor, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Grade II Meningioma, Adult Melanocytic Lesion, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pineal Gland Astrocytoma, Adult Pineocytoma, Recurrent Adult Brain Tumor
Interventions
proton beam radiation therapy, quality-of-life assessment, questionnaire administration
Radiation · Procedure · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 28, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)

NCT00093964
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Cilengitide 500 mg, Cilengitide 2000 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 28, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

NCT02076906
View directory record Official record
Conditions
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions
Magnetic Resonance High Intensity Focused Ultrasound
Device
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 28, 2026, 6:29 AM EDT
Terminated Phase 1 Interventional

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

NCT04596033
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions
GEN-011, IL-2, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 28, 2026, 6:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

How Does the Type of Waveform Affect Tolerability With Transcutaneous Auricular Vagus Nerve Stimulation?

NCT06614933
View directory record Official record
Conditions
Healthy
Interventions
Biphasic transcutaneous auricular vagus nerve stimulation, Monophasic transcutaneous auricular vagus nerve stimulation
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 28, 2026, 6:29 AM EDT